Results 61 to 70 of about 762 (132)

Comparison of patient-controlled intravenous analgesia with oliceridine or sufentanil on postoperative pain and quality of recovery in elderly patients after thoracoscopic pulmonary resection

open access: yesShiyong laonian yixue
[Objective] To compare the efficacy of oliceridine and sufentanil for patient-controlled intravenous analgesia (PCIA) in elderly patients after thoracoscopic pulmonary surgery, and to evaluate their impact on postoperative recovery quality.
CAI Yongliang   +3 more
doaj   +1 more source

Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug Monitoring

open access: yesPharmacology Research &Perspectives, Volume 13, Issue 6, December 2025.
ABSTRACT Polymyxin B (PMB), a last‐resort antibiotic for multidrug‐resistant Gram‐negative infections, carries significant neurotoxicity risks that remain underrecognized in clinical practice. Here, we present a case of life‐threatening diaphragmatic paralysis induced by PMB in a patient with extensive neck and mediastinal infections caused by ...
Yunli Zhang   +5 more
wiley   +1 more source

Evaluating biased agonism of glucagon‐like peptide‐1 (GLP‐1) receptors to improve cellular bioenergetics: A systematic review

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6105-6115, November 2025.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are highly effective antidiabetic and anti‐obesity agents. Recent development and optimisation of these agents includes biased agonism (selective activation of a downstream signalling pathway) of the GLP‐1 receptor, which has demonstrated greater weight‐lowering effects and improved insulin
Sabrina Wong   +4 more
wiley   +1 more source

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

open access: yesMedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan   +6 more
wiley   +1 more source

Opioid receptors in cardiovascular function

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 16, Page 3710-3725, August 2025.
Opioid receptors are G protein‐coupled receptors expressed by various cells in the heart, including myocytes and nerve fibres, and play a crucial role in modulating cardiac function. These receptors influence neural transmission, heart rate and myocyte contractility, offering cardioprotection.
Venkatesh Katari   +4 more
wiley   +1 more source

Differential G protein activation by the long and short isoforms of the dopamine D2 receptor

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 14, Page 3336-3352, July 2025.
Background and Purpose The dopamine D2 receptor is expressed as a short (D2S) and a long (D2L) isoform with 29 additional amino acids in the third intracellular loop. The D2S isoform shows higher presynaptic expression than the D2L isoform, and decreased D2S expression has recently been linked to an increased risk for schizophrenia.
David Reiner‐Link   +4 more
wiley   +1 more source

Progress on the development of Class A GPCR‐biased ligands

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 14, Page 3249-3300, July 2025.
Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales   +20 more
wiley   +1 more source

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years

open access: yesClinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1743-1753, June 2025.
Drug dose appropriateness is one of the most discussed issues in regulatory reviews. We analyzed dose determinations during Food and Drug Administration (FDA) drug reviews to determine whether there were changes between the proposed and approved doses of new molecular entities (NMEs), including cases where postmarketing dose‐finding studies were ...
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

New Insights Into Hepatic Impairment (HI) Trials

open access: yesClinical and Translational Science, Volume 18, Issue 1, January 2025.
ABSTRACT Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by ...
Sebastian Haertter   +4 more
wiley   +1 more source

Global Trends and Insights Into Opioid Utilization for Postoperative Pain Management: A Bibliometric Analysis (2014–2024)

open access: yesPain Research and Management, Volume 2025, Issue 1, 2025.
Background: Opioids are a class of potent analgesics extensively utilized for the management of moderate to severe pain. They are integral to postoperative analgesia, effectively mitigating pain following surgical interventions. The present study aims to undertake a comprehensive bibliometric analysis to evaluate research trends and focal areas within ...
Lingxian Kong   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy